Stockscreener 앱 받기
2.11
20.08%
-0.53
시장 영업 전:
2.17
0.06
+2.84%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest
Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest
Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - The Motley Fool
Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser
Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
Iovance falls after missing Q2 expectation - MSN
Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades Iovance Biotherapeutics Amid Lawsuit Turmoil - StocksToTrade
Iovance Shares Dip as CFO Changes and Legal Troubles Mount - timothysykes.com
Iovance Bio updates on Amtagvi - The Pharma Letter
Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade
Is Iovance’s Stock Plummet A Buying Chance? - timothysykes.com
Lacklustre Amtagvi launch forces Iovance to cut 19% of staff - FirstWord Pharma
Building trade automation scripts for Iovance Biotherapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Earnings call transcript: Iovance Biotherapeutics Q2 2025 misses revenue forecast - Investing.com
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening - Benzinga
Iovance Biotherapeutics Exceeds 100 Patient Milestone with Amtagvi Treatment for Advanced Melanoma, Q2 2025 Sales Reach $54 Million. - AInvest
Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption - MSN
Iovance Biotherapeutics (IOVA): Navigating Cost-Cutting and Global Expansion to Unlock Value in TIL Therapies - AInvest
Iovance Biotherapeutics: Strategic Restructuring and Amtagvi's Long-Term Potential in Immuno-Oncology - AInvest
Transcript : Iovance Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Iovance Biotherapeutics Inc (IOVA) Q2 2025 Earnings Call Highlig - GuruFocus
How to forecast Iovance Biotherapeutics Inc. trends using time seriesTrade Flow Monitor with Volume Tracker - Newser
Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025 - TipRanks
Iovance Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives - TipRanks
Bay Area biotech company once worth $4.4 billion lays off chunk of staff - SFGATE
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView
Iovance Biotherapeutics: Q2 Earnings Snapshot - News-Times
Iovance Biotherapeutics Reports Q2 2025 Financial Results - TipRanks
Iovance Biotherapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com
Iovance Biotherapeutics Q2 revenue up 60mln to 60mln; FY25 guidance reiterated. - AInvest
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewswire
Iovance Earnings: Revenue Soars 93% as Revolutionary Cancer Treatment Reaches Major Milestone - Stock Titan
Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer - TipRanks
Iovance Biotherapeutics to Cut Workforce by Less Than 20 Percent Amid Slower-Than-Expected Lifileucel Sales - geneonline.com
Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy - BioPharma Dive
Real time social sentiment graph for Iovance Biotherapeutics IncRisk-Managed Swing Setup and Signal Analysis - Newser
Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 17,191 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Chart based analysis of Iovance Biotherapeutics Inc. trendsFree Community Verified Stock Suggestions - Newser
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN
Allianz Asset Management GmbH Buys Shares of 20,300 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Will breakout in Iovance Biotherapeutics Inc. lead to full recoveryDaily Trade Setup Forecast with Confidence - Newser
0.24%
3.39%
자본화:
|
볼륨(24시간):